Yaghootkar, Hanieh2; Lamina, Claudia2; Scott, Robert A2; Dastani, Zari2; Hivert, Marie-France2; Warren, Liling L2; Stancáková, Alena2; Buxbaum, Sarah G2; Lyytikäinen, Leo-Pekka2; Henneman, Peter2; Wu, Ying2; Cheung, Chloe Yy2; Pankow, James S2; Jackson, Anne U2; Gustafsson, Stefan2; Zhao, Jing Hua2; Ballantyne, Christie M2; Xie, Weijia2; Bergman, Richard N2; Boehnke, Michael2; El Bouazzaoui, Fatiha2; Collins, Francis S2; Dunn, Sandra H2; Dupuis, Josee2; Forouhi, Nita G2; Gillson, Christopher2; Hattersley, Andrew T2; Hong, Jaeyoung2; Kähönen, Mika2; Kuusisto, Johanna2; Kedenko, Lyudmyla2; Kronenberg, Florian2; Doria, Alessandro2; Assimes, Themistocles L2; Ferrannini, Ele2; Hansen, Torben3; Hao, Ke2; Häring, Hans2; Knowles, Joshua W2; Lindgren, Cecilia M2; Nolan, John J2; Paananen, Jussi2; Pedersen, Oluf3; Quertermous, Thomas2; Smith, Ulf2; Lehtimäki, Terho2; Liu, Ching-Ti2; Loos, Ruth Jf2; McCarthy, Mark I2; Morris, Andrew D2; Vasan, Ramachandran S2; Spector, Tim D2; Teslovich, Tanya M2; Tuomilehto, Jaakko2; Willems van Dijk, Ko2; Viikari, Jorma S2; Zhu, Na2; Langenberg, Claudia2; Ingelsson, Erik2; Semple, Robert K2; Sinaiko, Alan R2; Palmer, Colin Na2; Walker, Mark2; Lam, Karen Sl2; Paulweber, Bernhard2; Mohlke, Karen L2; van Duijn, Cornelia2; Raitakari, Olli T2; Bidulescu, Aurelian2; Wareham, Nick J2; Laakso, Markku2; Waterworth, Dawn M2; Lawlor, Debbie A2; Meigs, James B2; Richards, J Brent2; Frayling, Timothy M2
1 Section for Metabolic Genetics, The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Section for Metabolic Genetics, The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, Københavns Universitet
Adiponectin is strongly inversely associated with insulin resistance and type 2 diabetes but its causal role remains controversial. We used a Mendelian randomisation approach to test the hypothesis that adiponectin causally influences insulin resistance and type 2 diabetes. We used genetic variants at the ADIPOQ gene as instruments to calculate a regression slope between adiponectin levels and metabolic traits (up to 31,000 individuals) and a combination of instrumental variables and summary statistics based genetic risk scores to test the associations with gold standard measures of insulin sensitivity (2,969 individuals) and type 2 diabetes (15,960 cases and 64,731 controls). In conventional regression analyses a 1 SD decrease in adiponectin levels was correlated with a 0.31 SD (95%CIs: 0.26-0.35) increase in fasting insulin, a 0.34 SD (0.30-0.38) decrease in insulin sensitivity and a type 2 diabetes odds ratio of 1.75 (95%CIs: 1.47-2.13). The instrumental variable analysis revealed no evidence of a causal association between genetically lower circulating adiponectin and higher fasting insulin (0.02 SD, 95%CI: -0.07, 0.11, N=29,771), nominal evidence of a causal relationship with lower insulin sensitivity (-0.20 SD; 95%CIs: -0.38, -0.02; N=1,860) and no evidence of a relationship with type 2 diabetes (odds ratio 0.94; 95%CIs: 0.75, 1.19; N= 2,777 cases and 13,011 controls). Using the ADIPOQ summary statistics genetic risk scores we found no evidence of an association between adiponectin lowering alleles and insulin sensitivity (effect per weighted adiponectin lowering allele: -0.03 SD, 95%CIs: -0.07, 0.01; N=2,969) or type 2 diabetes (odds ratio per weighted adiponectin lowering allele: 0.99; 95%CIs: 0.95, 1.04; 15,960 cases vs. 64,731 controls). These results do not provide any consistent evidence that interventions aimed at increasing adiponectin levels will improve insulin sensitivity or risk of type 2 diabetes.
Diabetes, 2013, Vol 62, Issue 10, p. 3589-3598
MOLECULAR-WEIGHT ADIPONECTIN GREATER-THAN-G PLASMA ADIPONECTIN ADIPOSE-TISSUE ASSOCIATION ANALYSES METABOLIC PROFILE GENETIC-VARIANTS SUPPRESSION TEST GLYCEMIC TRAITS OBESE WOMEN